Lantheus announced new data from a sub-analysis of its Phase 3 study on flurpiridaz F 18 for myocardial perfusion imaging (MPI) in obese patients. Findings from the research were presented at the American College of Cardiology’s 65th Annual Scientific Session.
Timothy Bateman, MD, the study’s lead author, explained that obese patients pose a “significant imaging challenge” and require better modalities to accurately examine this patient group.
The sub-analysis was based on data from a Phase 3 multicenter, international study (n=800). Of the total patients, 413 were obese with a BMI ≥30 and they underwent both rest and stress flurpiridaz F 18 PET and SPECT imaging and coronary angiography. Flurpiridaz F 18 PET imaging showed statistically greater sensitivity vs. MPI with single photon emission computed tomography (SPECT) for the assessment of coronary artery disease (CAD) in patients with a body mass index (BMI) ≥30 (71.1% vs. 51.7%; P<0.001). Specificity values were similar for flurpiridaz F 18 PET imaging vs. SPECT (79.8% vs. 77.5%; P=0.002).
In addition, a significantly higher percentage of images were rated as either excellent or good quality with flurpiridaz F 18 PET imaging vs. SPECT for stress images (P<0.001) and rest images (P<0.001). Flurpiridaz F 18 PET imaging also led to a significantly higher diagnostic certainty of interpretation vs. SPECT (P<0.001).
Flurpiridaz F 18 is an investigational positron emission tomography (PET) agent for MPI. It is a fluorine 18-labeled agent that binds to mitochondrial complex 1 (MC-1). The Company plans to begin the second of two Phase 3 studies for flurpiridaz F 18 PET imaging with a revised protocol in place.
For more information call (800) 362-2668 or visit Lantheus.com.